Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Canagliflozin vs Metformin: Canagliflozin has the stronger overall evidence (4.5 vs 4/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Canagliflozin wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Canagliflozin and Metformin have evidence — compare verdict strength side-by-side.
Off-label use mirrors diabetes dosing (e.g. 100–300 mg once daily before the first meal) under a clinician. A prescription drug; not an approved longevity regimen.
morning
Oral tablet (canagliflozin)
Off-label longevity use mirrors diabetes dosing (commonly 500–1500 mg/day of extended-release with meals) under a clinician. Not an approved longevity regimen, and unnecessary in well-controlled non-diabetics without a clear rationale.
with-meals
Extended-release tablet
Unknown in humans
Months to years
Weeks to months
Throughout use
Weeks
Years
Weeks of training
Days (GI) to years (B12)
Canagliflozin extends life span in genetically heterogeneous male but not female mice.
JCI insight (2020) · Animal
NIA Interventions Testing Program: canagliflozin extended lifespan in male mice
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine (2015) · Rct · n=7020
EMPA-REG OUTCOME randomized trial (empagliflozin, same class)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
The New England journal of medicine (2021) · Rct
EMPEROR-Preserved randomized trial (empagliflozin)
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Lancet (London, England) (1998) · Rct · n=753
UKPDS 34 randomized trial of metformin in overweight type-2 diabetics
Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis.
Ageing research reviews (2017) · Meta analysis
Systematic review/meta-analysis of metformin and age-related outcomes
Metformin as a Tool to Target Aging.
Cell metabolism (2016) · Review
Review of metformin's aging-relevant mechanisms (AMPK, insulin/IGF-1, inflammation)
Canagliflozin has a higher evidence score (4.5/10 vs 4/10) and wins in 1 of 3 categories.
For manage blood sugar, Metformin has a higher relevance score (72 vs 60).
No known interactions between Canagliflozin and Metformin have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.